Clinical Trials Browser

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00536107 2013-10-01

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 4 Terminated

14 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00090675 2013-01-29

IMAC/Herbst

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

Phase 3 Completed

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00608868 2012-09-28

SELINE

Phase 4 Completed

156 enrolled 14 charts

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00478049 2012-06-06

ISTANA

Phase 3 Completed

163 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01391260 2011-08-02

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00234468 2011-05-20

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Phase 3 Terminated

490 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00076388 2011-05-13

Iressa Versus Docetaxel (Taxotere)

Phase 3 Completed

1,440 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00255489 2011-01-25

A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

Phase 1 Completed

36 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00409006 2010-09-09

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Phase 2 Completed

70 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00344773 2010-06-29

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 2 Completed

46 enrolled 7 charts

Thoracic

Lung Neoplasms, Neoplasm Metastasis

NCT00264498 2009-08-03

Phase II Iressa & Carbo/Gem in NSCLC

Phase 2 Completed

38 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

RELAY

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

FLAURA

BM

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

DELINOR

ORCHARD

SOLAR

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

UpSwinG

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

MK-3475-021

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

IFUM

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

INSTEP

ICARUS

INFORM

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

A Study of LY2875358 in Japanese Participants With Advanced Cancer

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

IMAC/Herbst

Iressa Expanded Access Program (EAP)

SELINE

ISTANA

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Iressa Versus Docetaxel (Taxotere)

A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase II Iressa & Carbo/Gem in NSCLC